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Microalbuminuria in essential hypertension. Microalbuminuria is
frequently seen in patients with established essential hyperten-
sion, and is a predictor of a higher risk for cardiovascular and
probably renal dysfunction. The presence of microalbuminuria
has been shown to correlate with the other cardiovascular risk
factors commonly seen in hypertensive patients. This fact indi-
cates that the detection of an increased urinary albumin excretion
could probably be the best index of an increased global cardio-
vascular risk in a given patient. Blood pressure control is accom-
panied by a fall in the content of albumin in urine. Agents with the
capacity to block the renin-angiotensin system have shown a
capacity to decrease urinary albumin excretion, which is indepen-
dent of their ability to lower blood pressure. Whether or not a
decrease in urinary albumin excretion is accompanied by an
improved renal and cardiovascular prognosis in hypertensive
patients remains to be elucidated.
The term microalbuminuria is defined by a urinary
albumin excretion (UAE) rate higher than normal but
lower than 200 mg/min, the lowest detection limit of
proteinuria as measured by standard laboratory methods
[1, 2] in the absence of urinary tract infection and acute
illness including myocardial infarction [3]. A diagnosis of
microalbuminuria can be made by measuring its excretion
rate during 24 hours or in an overnight urine collection, or
by measuring albumin/creatinine ratio or albumin concen-
tration in the morning or a random urine sample (Table 1).
Determination of UAE in the morning urine sample con-
stitutes the ideal test for screening, and overnight urine
collection might be the best choice for monitoring mi-
croalbuminuria. The normal urinary excretion of albumin
oscillates between 1 and 22 mg/day and varies with posture,
exercise, and blood pressure; however, the day-to-day
variation is in the range of 31% to 52% [4, 5]. Therefore, a
mean of three urine collections has been recommended to
determine the UAE level of a given subject [1]. Different
assays can be used to measure UAE including several
semiquantitative tests that bring the test closer for general
practioners [4, 6]. The Micral-test is a test-strip method in
which the color reaction is mediated by an antibody-bound
enzyme. Nycocard U-albumin is a three drop test based on
a solid phase enzyme-linked immunosorbent assay. Both
methods have shown good correlations with radioimmuno-
assay and can be readily used for screening. The accepted
cut-off values for detection of microalbuminuria are 20
mg/min when assessed in 24-hour urine collection [5, 7].
However, a recent study suggest that the risk for cardio-
vascular disease in arterial hypertension is increased at
even lower UAE levels of 15 mg/min [8].
It is now apparent that between 5 and 10% of nondia-
betic individuals have a UAE within the microalbuminuric
range [9]. Initial studies indicated that microalbuminuria
may be a strong predictor of mortality of cardiovascular
origin [10–13]. Nevertheless, it could not be concluded
whether microalbuminuria is a predictor in its own value, or
whether it is the association with other risk factors that is of
importance. In this sense, elevated UAE has been shown to
be related to elevated serum triglycerides and low high-
density lipoprotein cholesterol, obesity, glucose intoler-
ance, insulin resistance and uric acid levels [7, 14–18]. An
association between smoking, alcohol intake and mi-
croalbuminuria has also been shown [7, 19, 20]. Patients
with microalbuminuria are older and exhibit predominant
male gender, as compared with normoalbuminuric subjects
[8, 17]. Finally, a correlation between systemic blood pres-
sure and UAE has been found not only in hypertensive
patients [7, 8, 17], but in the general population [21, 22].
Interestingly, recent data by Jiang et al indicate that the
association between blood pressure and UAE is stronger in
blacks than in whites [22], which supports the notion that
blacks may be more susceptible to renal damage from
relatively low levels of blood pressure increase.
MECHANISMS OF MICROALBUMINURIA
Increased UAE could be the consequence of an aug-
mented intraglomerular capillary pressure, it could reflect
the existence of intrinsic glomerular damage that causes
changes in glomerular barrier filtration, or it could be the
consequence of a tubular alteration that impedes the
normal reabsorption of filtered albumin. However, it has
been suggested that microalbuminuria may represent the
renal manifestation of generalized, genetically-conditioned
Key words: calcium antagonists, cardiovascular risk, angiotensin convert-
ing enzyme inhibitors, microalbuminuria, nephrosclerosis.
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54, Suppl. 68 (1998), pp. S-51–S-54
S-51
vascular endothelial dysfunction that may underlie the link
between an increased UAE and an elevated risk for
cardiovascular disease [23, 24]. In this sense, it has been
described that microalbuminuria is associated with a de-
creased size- and charge-selectivity of the glomerular vessel
wall in clinically healthy subjects [25], and is an indepen-
dent marker of systemic transvascular albumin leakiness
[26]. Furthermore, atherosclerotic vascular disease is asso-
ciated with renal and systemic transvascular leakiness for
albumin [27]. A defective endothelial permeability could
then be the origin of microalbuminuria in the general
population. Some recent findings support an eventual
relationship between microalbuminuria and endothelial
dysfunction in hypertension that includes a positive corre-
lation of UAE and circulating von Willebrand Factor
antigen, Factor VII hyperactivity, fibrinogen and endothe-
lial cell damage [24, 28, 29]. However, when endothelial
function was directly assessed through acetylcholine vaso-
dilatory action no correlation with UAE was found [30].
Others mechanisms could be implicated in the presence
of microalbuminuria in essential hypertension. Such mech-
anisms include renal hemodynamic changes due to the
direct transmission of increased systemic pressure to the
glomeruli [31–33], permselectivity changes of the glomeru-
lar filter and/or insufficient tubular reabsorption of albumin
[32, 34], and structural damage to the glomeruli and
arterioles [33]. In favor of a significant role of elevated
systemic blood pressure facilitating the transglomerular
passage of albumin is the significant positive correlation
found between office blood pressure levels and UAE by
most groups [20, 31, 35–38]. The correlation is more
pronounced when UAE values are plotted against ambu-
latory blood pressure values [37, 39, 40]. In this sense
systolic blood pressure has been shown to be one of the
most relevant determinants of microalbuminuria in the
early stages of hypertensive disease [41]. On the other
hand, higher levels of UAE have been described in those
patients not exhibiting a nocturnal fall in blood pressure
(non-dippers), indicating that a greater degree of renal
involvement could be present in this particular group of
patients [39, 40].
MICROALBUMINURIA AS A RISK IN ESSENTIAL
HYPERTENSION
In 1974 Parving et al reported the finding of elevated
UAE levels in insufficiently treated essential hypertensives,
which correlated significantly with blood pressure levels
and fell after blood pressure control [31]. This finding has
been amply confirmed and it is now recognized that
microalbuminuria can be found in up to 40% of untreated
hypertensive population [32, 35, 42]. Prevalence of an
elevated UAE increases with age, and with longer duration
and a higher severity of hypertension [41, 43]. In treated
patients prevalence can be as high as 25% when diuretics
and beta-blockers are used [33, 44].
Hypertensive target organ damage is more common in
microalbuminuric patients [8, 17, 43–45]. Patients with
elevated UAE have higher left ventricular mass [38, 43, 45,
46], a higher prevalence of hypertensive retinopathy [47],
and an increased thickness and presence of plaques in the
carotid artery [48, 49]. Furthermore, the presence of mi-
croalbuminuria in essential hypertensive patients has been
interpreted as a marker of early intrarenal vascular dys-
function in essential hypertension [43, 49, 50]. An absence
of the capacity of the renal vasculature to vasodilate in
response to an intravenous amino acid infusion [50] or to
an ACE inhibitor [51] is present in patients with microalbu-
minuria. These findings could be of great relevance for two
reasons, first because the existence of functional renal
vasoconstriction since the very early stages of essential
hypertension contributes to the development of high blood
pressure [52]; second because microalbuminuria could be a
marker of the presence of nephrosclerosis [33, 43, 45, 53].
In summary, microalbuminuria is an independent predictor
of cardiovascular morbidity and mortality in both men and
women with essential hypertension [2, 10, 42, 54]. This
could, in turn, be facilitated by the frequent association of
an elevated urinary albumin excretion to a series of alter-
ations, such as endothelial dysfunction, insulin resistance,
altered lipid levels, higher body mass index, increased
serum uric acid and salt-sensitivity [17, 24, 28, 29, 55–58].
All these alterations could facilitate the accompanying risk
for atherosclerosis, and it likely explain such an association
between UAE and the risk of coronary heart disease [29].
Interestingly, in a recent work Berton et al describe that
the known increase of UAE during acute miocardial infarc-
tion strongly predicts in-hospital mortality, and this prog-
nostic information is greater and independent to other
clinical markers [59]. The rise in UAE was attributed to a
systemic increase in vascular permeability as part of the
acute inflammatory process that accompanies the myocar-
dial infarction [60].
Clustering microalbuminuria with other cardiovascular
risk factors contributes to considering that microalbumin-
uria in essential hypertension has a genetic origin [55–58].
In conclusion, microalbuminuria seems to constitute a
simple and accurate method to detect a hypertensive
patient at a high risk for cardiovascular and probably renal
damage.
While a decrease in UAE in essential hypertension is
currently thought to be beneficial for the patient, this
Table 1. Definition of microalbuminuria
Excretion rate 20–200 mg/min (valid for overnight
urine collection
30–300 mg/24 hr
Albumin/creatinine ratio 2.5–25 mg/mmol (Europe)
30–300 mg/g (USA)
Albumin concentration
(early morning urine)
30–300 mg/liter
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assertion remains to be proven. In this sense, antihyperten-
sive therapy of any kind is able to lower UAE in essential
hypertensives by simply lowering blood pressure [2], and
both systolic and diastolic blood pressure reductions are the
most important factors associated with a UAE decrease
[61]. Nevertheless, ACE inhibitors have been shown to
exhibit a higher capacity to decrease microalbuminuria in
hypertensive patients that goes beyond their capacity to
decrease renal perfusion pressure [2, 62]. Only some stud-
ies using angiotensin II receptor antagonists show a capac-
ity in reducing UAE close to ACE inhibitors [63], suggest-
ing that glomerualr leakage of albumin is profoundly
affected by the effects on angiotensin II.
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